Akari Therapeutics Shares Jump As KRAS Cancer News Returns

Akari Therapeutics looked set to surge at the open Friday. The biotech said its main cancer drug posted positive preclinical data in KRAS-mutated pancreatic cancer and announced a $5.5 million private placement. Akari closed up nearly 50% at $5.14 on Thursday. Shares were quoted at $10.15 as of 8:39 a.m. EDT in premarket, StockAnalysis reported.